Gilenya Cuts in Fall 2014

Discussion in 'Novartis' started by Anonymous, Mar 31, 2014 at 1:05 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    No more dual covered territories. That is a fact!
     

  2. Anonymous

    Anonymous Guest

    Hmmmm the deal is inked genius. 80-90 percent cuts coming. That is a fact. Why keep throwing good money after bad. The only reason we are keeping 20-30 reps plus SAMs is so we keep relationships going with KOLs in anticipation for new product launch in 2018. Until then watch out!
     
  3. Anonymous

    Anonymous Guest

    Then answer the question skippy. Why are we spending hundreds of thousands on speaker programs,patient programs if all we want to do is cut costs. ECTRIMS is coming up and every KAM,SAM marketing member are attending. That will cost novartis millions yet we are cutting back according to you. Sorry nothing you say adds up plus they filling open territories.
     
  4. Anonymous

    Anonymous Guest

    They just spent 500k on preceptorships across the country how are we cutting back?
     
  5. Anonymous

    Anonymous Guest

    Need advice: A top KOL told me he does not want the SAM to come see him anymore because the SAM is lacking MS clinical knowledge. This is the SAM top account. Any advice?
     
  6. Anonymous

    Anonymous Guest

    We all have the same problem. My SAM is useless brings nothing new to the table. Add this to the list of failures for the leadership team.
     
  7. Anonymous

    Anonymous Guest

    I guess the SAM experiment didn't work.Another failure.Wonder what will happen to the SAMs.
     
  8. Anonymous

    Anonymous Guest

    Company thrives on drones like you who don't see anything coming until they tell you to stay home and wait for your call to learn your fate. Keep your nose to the grind Homer. You have 3 months to keep driving share and saving patient lives. HAHAHAHA
     
  9. Anonymous

    Anonymous Guest

    Hey Skippy were you let go from Novartis so you are spreading fake rumors. How the hell do you know what's going to happen. Difference between you and me I will find another job. You will troll cafe pharma and jerk off to internet porn all day. Your family must be very proud of you.
     
  10. Anonymous

    Anonymous Guest

    You appear very skilled in the expert trade of being a unemployed Pharma nut.
     
  11. Anonymous

    Anonymous Guest

    Betting on further rep job cuts in the US pharma industry over the last 4 years would have won you some money since between 2010 and now ~ 40% or 40,000 rep jobs have the industry. And all smart money says that there are many more to come

    And watching this carnage would be thrill for many who get off to snuff flicks.
     
  12. Anonymous

    Anonymous Guest

    People please quit feeding these trolls! There will be NO LAYOFFS in MSBU. End of story!!! Billion dollar drug with 110 reps nationwide. We are the leanest MS salesforce and the ROU per rep is highest in company. We have the PPMS indication coming up also. Why would Novartos layoff it's already small salesforce on the eve of this new indication??? There are too many jealous idiot trolls on this thread! Get a life!
     
  13. Anonymous

    Anonymous Guest

    Of course there won't be cuts. Too many people are leaving on their own. The allure of launching a 1st of class oral is gone. micro management is here to stay. A large majority getting a poor bonus is here to stay. It is just not fun anymore. dreadful is the word for working in the MSBU. Horrible leadership. Until I find something else I will do my best to tell the truth so anyone thinking about coming to the MSBU thinks twice.
     
  14. Anonymous

    Anonymous Guest

    In November, you will hear of an announcement regarding the MSBU. Yes, there will be cuts. Revenues, not merely sales are a focal point. White space methodology will be used to ensure productivity goals are met. This will happen.
     
  15. Anonymous

    Anonymous Guest

    Let's do some smile math for your pea sized brain. Gilenya does over 1 Billion in sales (aka revenue). There are 100 reps nationwide. That means the ROI per rep on Gross Revebues is 10 million! Yes we give 1/2 to Mitsubishi Group (not quite but okay) 5 million! Yes we have a rep cost about 500k per year! That still is a 10x ROI per rep!!! You still think Novartis will cut it's golden goose? In eve of PPMS indication? Quit spreading fears and go back to your Biogen Board and 3 person territory!
     
  16. Anonymous

    Anonymous Guest

    Reps have nothing to do with the sales. It will go on without them.
     
  17. Anonymous

    Anonymous Guest

    Why keep any reps at all then? Lay off 100 percent
     
  18. Anonymous

    Anonymous Guest

    You are so smart. I guess there are no managers, HR, marketing costs, legal, etc associated with Gilenya. It doesn't matter if they make $5 million a rep, it is all about saving money and eliminating waste. 2 reps in a territory a waste. Gilenya underperforming means cuts. You can sit back and wait or start looking and leave like the smart reps. It might happen in October or December or maybe in 2015. It will happen. It sucks here with the micro management and poor bonuses in 2014. Why wait? There is nothing here except a paycheck which is replaceable and the knowledge that cuts are coming. Does anyone truly believe the MSBU is a good place to be??????????
     
  19. Anonymous

    Anonymous Guest

    Your attempt at a reductio ad absurdum argument may be seem to be clever but it masks the underlying logic that is being used to decimate all pharma reps, not just Gilenya. Since now, due to access and other issues, there is almost no correlation between sales reps and total sales, pharma is cutting reps. They have, industry wide, now slashed 40% with no effect on sales and with no end in site.

    Most of the incentives NOT to cut even more is institutional; what do sales leadership and marketing do if there aren't many sale reps? What is the sales strategy if there aren't many or any sales reps?

    I repeat, sales rep numbers have been cut in the US industry wide by 40% over the last 4 years and overall sales are up.

    And it's not just the direct costs of reps that pharma feels. Employing reps has risks. With the new Sunshine Laws and all the lawsuits Reps pose a big risk.

    No, pharma will not get rid of all Reps but it ain't stopping at a 40% reduction.
     
  20. Anonymous

    Anonymous Guest

    Very true. Word is announcement will be Oct/Nov with Jan 1 effective date.